羟基脲联合干扰素治疗糖尿病合并真性红细胞增多症疗效观察  

Therapeutic Effect of Hydroxyurea Combined with Interferon on Diabetes Mellitus Complicated with Polycythemia Vera

作　　者：崔璐[1] CUI Lu(Department of Hematology, Changchun Central Hospital, Changchun, Jilin Province, 130000 China)

机构地区：[1]长春市中心医院血液内科,吉林长春130000

出　　处：《糖尿病新世界》2019年第7期73-74,共2页Diabetes New World Magazine

摘　　要：目的探讨羟基脲联合干扰素治疗糖尿病合并真性红细胞增多症的效果。方法选取该科2016年6月—2018年6月收治的42例糖尿病合并PV患者,随机分为两组,各21例,观察组采用羟基脲联合干扰素治疗,对照组采用羟基脲治疗。结果观察组总有效率为90.5%,显著高于对照组76.2%(P<0.05);两组FPG比较差异无统计学意义(P>0.05),观察组Hb、RBC、PLT、HCT较对照组显著下降(P<0.05)。结论羟基脲联合干扰素治疗糖尿病合并PV能有效抑制骨髓成纤维细胞的增殖,改善症状和预后。Objective To investigate the effect of hydroxyurea combined with interferon in the treatment of diabetes complicated with polycythemia. Methods Forty-two patients with diabetes mellitus complicated with PV admitted to our department from June 2016 to June 2018 were randomly divided into two groups: 21 patients each. The observation group was treated with hydroxyurea combined with interferon, and the control group was treated with hydroxyurea. Results The total effective rate of the observation group was 90.5%, which was significantly higher than that of the control group (76.2%)(P<0.05). There was no difference in FPG between the two groups (P>0.05). The Hb, RBC, PLT and HCT of the observation group decreased significantly compared with the control group (P<0.05). Conclusion Hydroxyurea combined with interferon can effectively inhibit the proliferation of bone marrow fibroblasts and improve the symptoms and prognosis of diabetic patients with PV.

关 键 词：羟基脲 干扰素 糖尿病 真性红细胞增多症 

分 类 号：R587.1[医药卫生—内分泌]